1Owczarek D, Cibor D, Szczepanek M, et al. Biological therapy of inflammatory bowel disease [ J ] . Pol Arch Med Wewn, 2009, 119 ( 1-2 ) : 84-88.
2Cao SS, Zimmermann EM, Chuang BM, et al. The unfolded protein response and chemical chaperones reduce protein misfolding and colitis in mice [ J ] . Gastroenterology, 2013, 144 ( 5 ) : 989.
3Berger E, Hailer D. Structure-function analysis of the tertiary bile acid TUDCA for the resolution of endoplasmic reticulum stress in intestinal epithelial cells [ J ] . Biochem Biophys Rcs Commun, 2011, 409 (4) : 610-615.
4Martinez-Moya P, Romero-Calvo I, Requena PA, et al. Dose- dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis [J] . Int Immunopharmacol, 2013, 15 ( 2 ) : 372-380.
5Murano M, Maemura K, Hirata I, et al. Therapeutic effect of intracolonically administered nuclear factor kappa B ( p65 ) antisense oligonucleotide on meuse dextran sulphate sodium ( DSS ) -induced colitis [ J ]. Clin Exp Immunol, 2000, 120 ( 1 ) : 51-58.
6Duboc H, Rajca S, Rainteau D, et al. Connecting dysbiosis, bile- acid dysmetabolism and gut inflammation in inflammatory bowel diseases [ J ] . Gut, 2013, 62 ( 4 ) : 531-539.
7Stenman LK, Holma R, Forsgard R, et al. Higher fecal bile acid hydrophobicity is associated with exacerbation of dextran Sodium sulfate colitis in mice [ J ]. J Nutr, 2013, 143 ( 11 ) : 1691-1697.
8Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis : results of a randomised controlled trial [ J ] . Gut, 2011, 60 (6): 780-787.
9Sandborn WJ, Van Assche G, Reinisch WA, et al. Adalimumab induces and maintains clinical remission in patients with Moderate- to-Severe ulcerative colitis [ J ] . Gastroenterology, 2012, 142 ( 2 ): 257-U150.
10Li Y, De Haar C, Chen M, et al. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis [ J ] . Gut, 2010, 59 ( 2 ) : 227-235.
